According to our latest research, the global Ublituximab market size reached USD 1.22 billion in 2025, reflecting the rapid and sustained adoption of this glycoengineered anti-CD20 monoclonal antibody in the treatment of hematological malignancies and autoimmune diseases. The market is experiencing strong momentum, with a forecast CAGR of 12.7% between 2026 and 2034. By 2034, the Ublituximab market is projected to attain a value of approximately USD 3.57 billion, driven by expanding indications, rising prevalence of multiple sclerosis and chronic lymphocytic leukemia, and continuous advancement of novel therapeutic protocols. The market's robust trajectory is underpinned by both demonstrated clinical efficacy and a widening global patient base that is increasingly receiving biologic-based care. https://growthmarketreports.com/report/ublituximab-market